Abbott Laboratories stock (US0028241000): diabetes growth and fresh guidance keep investors focused

Abbott Laboratories has reported higher Q1 2026 earnings, raised its full-year EPS guidance and underlined strong momentum in diabetes care and medical devices, while the stock trades well below average analyst targets.

Abbott Laboratories has started 2026 with higher earnings, updated guidance and continued momentum in its medical device and diabetes care businesses, even as the share price remains under pressure compared with recent years, according to the company’s first?quarter 2026 results and subsequent market commentary published in April and May 2026 by the group and major financial media.

In mid?April 2026, Abbott reported adjusted earnings per share (EPS) of around $1.15 on revenue of about $11.16 billion for the first quarter of 2026, slightly ahead of Wall Street expectations and up roughly 7.8% year over year, and the company simultaneously confirmed or narrowed its full?year 2026 EPS guidance range and provided an updated outlook for key segments, according to the earnings release and coverage by international business media as of April 2026, as summarized by MarketBeat as of 05/17/2026 and Ad-hoc-news as of 04/2026.

As of: 18.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Abbott Laboratories
• Sector/industry: Healthcare, medical devices and diagnostics
• Headquarters/country: Abbott Park, Illinois, United States
• Core markets: United States, Europe, Latin America, Asia-Pacific and other international regions
• Key revenue drivers: Medical devices, diabetes care, diagnostics, nutrition, established pharmaceuticals
• Home exchange/listing venue: New York Stock Exchange (ticker: ABT)
• Trading currency: US dollar (USD)

Abbott Laboratories: core business model

Abbott Laboratories is a diversified healthcare company with a long history in diagnostics, medical devices, nutrition and branded generic pharmaceuticals, and it has grown into one of the larger US?listed healthcare groups by combining internal research with targeted acquisitions, according to company information and sector overviews published on its website and in investor presentations in recent years.

The diagnostics division supplies laboratory instruments and assays used by hospitals and reference labs worldwide, covering areas such as core lab testing, point?of?care diagnostics and molecular diagnostics, while the medical devices arm focuses on cardiology, structural heart, neuromodulation and particularly diabetes care with its FreeStyle Libre glucose monitoring systems, as highlighted in the company’s first?quarter 2026 earnings communication and follow?up commentary by financial media in April 2026.

Nutrition is another pillar of Abbott’s business model, encompassing infant formulas, pediatric nutrition products and adult nutrition brands that are sold primarily through retail and healthcare channels, whereas the established pharmaceuticals segment provides branded generic medicines in emerging markets, where rising disposable incomes and expansion of healthcare coverage support structural demand, according to management remarks cited in the Q1 2026 update and coverage from international business outlets as of April 2026.

The group’s diversified structure means that no single product line accounts for the majority of revenue, which can reduce reliance on individual franchises but also requires sustained investment in research, development, manufacturing and regulatory compliance across multiple sub?sectors of healthcare, something Abbott continues to highlight as a core element of its long?term strategy in investor presentations and earnings calls over the past several years.

Main revenue and product drivers for Abbott Laboratories

In the first quarter of 2026, Abbott reported that total revenue rose at a mid?single to high?single?digit rate year over year and emphasized that medical devices, and especially diabetes care, were central growth engines, with diabetes care revenue increasing at a double?digit pace, driven by continued adoption of FreeStyle Libre glucose monitoring systems in the United States and international markets, according to the Q1 2026 earnings release and coverage summarized by Ad-hoc-news as of 04/2026.

Management cited strong uptake among type 2 diabetes patients and expanding reimbursement for continuous glucose monitoring in several countries as key drivers for Libre, while also pointing to growth contributions from cardiovascular and structural heart devices, including products used in minimally invasive procedures, according to comments referenced in the Q1 2026 earnings communication and a conference call transcript cited by international financial media in April 2026.

Beyond devices, Abbott indicated that core laboratory diagnostics volumes were stable to slightly higher in the latest quarter, even as revenue from COVID?19 tests continued to decline versus the prior?year period, and the company stressed that the pandemic?related testing windfall is now largely behind it, with investors encouraged to focus on underlying diagnostics growth and market?share trends rather than year?on?year comparisons distorted by COVID testing, according to the Q1 2026 results and media analysis as of April 2026.

In nutrition, management described performance as steady, highlighting ongoing recovery in US infant formula operations following previous disruptions and growth in certain adult nutrition lines, while established pharmaceuticals delivered relatively stable cash flows, benefiting from demand for branded generics in regions such as Latin America and parts of Asia, according to the same April 2026 sources summarizing the company’s segment disclosures.

Overall, Abbott’s leadership reiterated that capital allocation priorities include continued investment in research and development, selective acquisitions to strengthen existing franchises, and ongoing returns to shareholders through dividends and share repurchases, with these priorities framed within the context of the reaffirmed or slightly adjusted 2026 EPS guidance given alongside the first?quarter 2026 results, according to the guidance section of the earnings release and subsequent coverage in major US financial media in April 2026.

Industry trends and competitive position

Abbott operates in several competitive healthcare markets where long product cycles, regulatory oversight and reimbursement structures shape growth prospects, and in diabetes technology it competes with other global players offering continuous glucose monitoring and insulin delivery systems, with analysts noting that the FreeStyle Libre franchise has helped the company gain share in the broader glucose monitoring space, according to sector analysis and earnings commentary referenced by financial media in April and May 2026.

In diagnostics, the company is part of a concentrated group of multinational suppliers of laboratory instruments and assays, and post?pandemic dynamics involve normalizing COVID?related testing alongside ongoing demand for routine and specialty testing, while in cardiovascular and structural heart devices Abbott faces competition from other large medtech firms, yet industry observers often point to the long?term tailwind of aging populations and rising prevalence of chronic cardiovascular conditions, as discussed in recent healthcare sector reports and commentary as of 2025 and 2026.

The nutrition and established pharmaceuticals businesses are more exposed to consumer behavior and pricing pressures, but they also provide geographic and product diversification and can benefit from macro trends such as growing middle classes in emerging markets, expanding healthcare coverage and increased focus on preventive care and nutritional support, according to company descriptions and international business media coverage from 2025 and 2026.

Why Abbott Laboratories matters for US investors

For US investors, Abbott is notable as a large, diversified healthcare stock listed on the New York Stock Exchange and included in several major indices, meaning its performance can influence healthcare sector benchmarks and diversified portfolios, while its product portfolio offers exposure to structural trends in chronic disease management, diagnostics and medical technology innovation, according to index overviews and sector commentaries published by major financial institutions through 2025 and 2026.

The company’s regular dividend payments and long record of annual dividend increases are also frequently highlighted by income?oriented investors, and the most recent quarterly dividend of $0.63 per share, equivalent to an annualized payout of around $2.52, was paid in mid?May 2026 to shareholders of record in April 2026, corresponding to a yield of roughly 3% at share prices reported in mid?May 2026, according to coverage by MarketBeat as of 05/17/2026.

At the same time, the stock has faced valuation and sentiment swings, with some recent reports noting that shares traded around the mid?$80s in May 2026 compared with an average analyst price target near $119, while the consensus rating stood in the Moderate Buy range, based on aggregated analyst data cited by MarketBeat and other financial portals as of mid?May 2026, underscoring both the perceived long?term potential and the shorter?term caution in the market.

Risks and open questions

Despite the broadly positive tone of the Q1 2026 results and guidance, Abbott faces several risks and uncertainties, including potential pricing and reimbursement changes in key markets, competitive pressure in devices and diagnostics, and ongoing scrutiny of its nutrition business following past operational challenges, as referenced in valuation and risk discussions by financial commentators in 2025 and 2026, including an analysis of legal and reputational issues related to nutrition published by Sahm Capital in May 2026.

Regulatory developments can also affect the timing of new product approvals and market launches, while macroeconomic factors such as currency fluctuations and economic slowdowns in emerging markets may influence reported revenue and profitability, and the company itself has acknowledged in its guidance commentary that normalization of COVID?related testing and adverse currency movements remain headwinds for reported growth in 2026, according to its April 2026 earnings and outlook communication.

Investors additionally monitor Abbott’s capital allocation decisions, including the balance between dividends, share repurchases, debt management and investment in organic growth or acquisitions, recognizing that a shift in priorities or an unexpectedly large acquisition could alter the company’s risk and return profile, a topic that features regularly in analyst calls and shareholder discussions as documented in financial media coverage through 2025 and 2026.

Key dates and catalysts to watch

Looking ahead, one of the next formal catalysts for Abbott will be the publication of its second?quarter 2026 results, for which the company has issued guidance on expected EPS ranges, and investors will examine whether the strong trends in diabetes care and medical devices continue, whether diagnostics growth normalizes at attractive levels without COVID testing, and how the nutrition recovery progresses, according to guidance commentary and consensus expectations cited by MarketBeat and other financial outlets as of May 2026.

In addition, the company has already announced that it plans to release its fourth?quarter 2025 financial results on January 22, 2026, followed by a conference call with analysts, which was flagged in a January 5, 2026 press notice distributed via PR Newswire and summarized by StockTitan, and while that date is now in the past, similar quarterly calls remain important events where management provides detailed updates on strategy, capital allocation and regulatory or competitive developments relevant for the investment case.

Conclusion

Abbott Laboratories enters the remainder of 2026 with a mix of strengths and challenges: revenue is growing, particularly in medical devices and diabetes care, the company maintains a diversified portfolio across diagnostics, nutrition and established pharmaceuticals, and management has reaffirmed or slightly raised guidance despite headwinds from declining COVID testing and currency effects, according to its April 2026 results and outlook statements.

For US investors, the stock offers exposure to major healthcare themes and a long history of dividend payments, yet recent valuation debates and softer sentiment reflect concerns about execution in nutrition, competitive dynamics in key segments and macro risks, as highlighted by market commentary and analyst discussions in 2025 and 2026, suggesting that future share price performance will depend heavily on the company’s ability to sustain segment growth, navigate regulatory and competitive pressures and deliver on its stated financial targets over the coming quarters.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.